GSK’s Efimosfermin Improves Liver Fibrosis Markers in Phase II Trial
GSK said efimosfermin improved liver fibrosis markers in a Phase II trial.
Related stories
Wells Fargo hires restructuring banker Philip Saliba from Deutsche Bank
Wells Fargo hired veteran restructuring banker Philip Saliba from Deutsche Bank; no further details or catalyst were supplied.
L impact | EQUITY | Nov 05, 2026, 03:46 PM UTC
Data-Center and Chip Stocks Extend Declines After Democrats Win Congress
Cloud-infrastructure and chip stocks continued to fall in early trade Thursday, two days after Democrats' midterm victory. Investors reassessed bets on stocks tied to the AI buildo
M impact | EQUITY | Nov 05, 2026, 03:45 PM UTC
MNTN Stock Down More Than 50% After Sales Force Disruption and Reduced Outlook
MNTN shares are reported down more than 50% following a sales force disruption and reduced financial outlook.
M impact | EQUITY | Nov 05, 2026, 03:45 PM UTC
Truelink Capital Acquires CSG Creative for GES Platform
Truelink Capital said it acquired CSG Creative, an association marketing and creative agency, to expand its GES platform.
M impact | EQUITY | Nov 05, 2026, 03:45 PM UTC
ScanSource Shares Fall 11.5% After Fiscal Q1 Earnings Miss
ScanSource shares were down 11.5% after the company reported lower fiscal first-quarter non-GAAP earnings that missed estimates.
M impact | EQUITY | Nov 05, 2026, 03:44 PM UTC
N-able Shares Rise 2.7% After Q3 Results Top Estimates
N-able shares rose 2.7% in Thursday trading after its third-quarter results topped estimates.
M impact | EQUITY | Nov 05, 2026, 03:44 PM UTC